Abstract
Pertuzumab is a humanized monoclonal antibody inhibiting human epidermal growth factor receptor 2 (HER2) dimerization. The aim of this phase II trial was to assess the antitumor activity and safety profile of pertuzumab monotherapy in patients with HER2-negative metastatic breast cancer. The utility of biomarkers detected in paraffin-embedded tissue as predictors of response was also explored.
Original language | English |
---|---|
Pages (from-to) | 1131-7 |
Number of pages | 7 |
Journal | Journal of Clinical Oncology |
Volume | 28 |
Issue number | 7 |
DOIs | |
Publication status | Published - 2010 |
Keywords / Materials (for Non-textual outputs)
- Adult
- Aged
- Antibodies, Monoclonal
- Breast Neoplasms
- Dimerization
- Female
- Humans
- Middle Aged
- Neoplasm Metastasis
- Receptor, erbB-2
- Ventricular Function, Left